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OBJECTIVE — To re-evaluate the relationship between glycemia and diabetic retinopathy.
RESEARCH DESIGN AND METHODS — We conducted a data-pooling analysis of
ninestudiesfromﬁvecountrieswith44,623participantsaged20–79yearswithgradableretinal
photographs. The relationship between diabetes-speciﬁc retinopathy (deﬁned as moderate or
more severe retinopathy) and three glycemic measures (fasting plasma glucose [FPG; n 
41,411],2-hpostoralglucoseloadplasmaglucose[2-hPG;n21,334],andA1C[n28,010])
was examined.
RESULTS — When diabetes-speciﬁc retinopathy was plotted against continuous glycemic
measures, a curvilinear relationship was observed for FPG and A1C. Diabetes-speciﬁc retinop-
athyprevalencewaslowforFPG6.0mmol/landA1C6.0%butincreasedabovetheselevels.
Based on vigintile (20 groups with equal numbers) distributions, glycemic thresholds for dia-
betes-speciﬁc retinopathy were observed over the range of 6.4–6.8 mmol/l for FPG, 9.8–10.6
mmol/l for 2-h PG, and 6.3–6.7% for A1C. Thresholds for diabetes-speciﬁc retinopathy from
receiver-operating characteristic curve analyses were 6.6 mmol/l for FPG, 13.0 mmol/l for 2-h
PG, and 6.4% for A1C.
CONCLUSIONS — This study broadens the evidence based on diabetes diagnostic criteria.
A narrow threshold range for diabetes-speciﬁc retinopathy was identiﬁed for FPG and A1C but
notfor2-hPG.ThecombinedanalysessuggestthatthecurrentdiabetesdiagnosticlevelforFPG
could be lowered to 6.5 mmol/l and that an A1C of 6.5% is a suitable alternative diagnostic
criterion.
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T
he current diagnostic cut points for
diabetes (fasting plasma glucose
[FPG] of 7.0 mmol/l and 2-h post
oralglucoseloadplasmaglucose[2-hPG]
of 11.1 mmol/l) are largely based on gly-
cemic levels associated with a substan-
tiallyincreasedriskofdiabetes-associated
microvascularcomplications,particularly
retinopathy, above these levels (1,2).
Thesecutpointswerederivedfromcross-
sectional epidemiological studies that ex-
amined retinopathy across a range of
glycemic levels. The datasets used for this
purpose were from Pima Indians, an
Egyptian study, and unpublished data
from the Third National Health and Nu-
trition Examination Survey (NHANES)
(2).
Other studies (3–5) also have exam-
inedthisrelationship,buttheresultshave
been inconsistent. All studies reported to
date have had limited statistical power to
examine this relationship in detail and
have adopted a very broad deﬁnition of
retinopathy that included many cases of
mild retinopathy, now known to have
causes other than hyperglycemia (6). A
more clinically relevant end point is dia-
betes-speciﬁc retinopathy (moderate or
more severe levels of retinopathy) that is
invariably attributed to hyperglycemia.
Also different statistical methods have
been used in previous studies, which has
an important effect on derived cut points
(5,7).
Severalnewdatasetswithretinopathy
datahavebecomeavailablesincetheorig-
inal studies used to derive current diabe-
tes diagnostic cut points (1,2). The
DETECT-2 collaboration has pooled
these datasets to examine and re-evaluate
the relationship between retinopathy and
three glycemic measures: FPG, 2-h PG,
andA1C.ThesizeoftheDETECT-2data-
sethasallowedustofocusontherelation-
ship between measures of glycemia and
diabetes-speciﬁc retinopathy (i.e., mod-
erate or more severe levels of retinopa-
thy). These analyses were designed to
inform current deliberations on possible
revisions to the diagnostic criteria for
diabetes.
RESEARCH DESIGNS AND
METHODS— The DETECT-2 project
is an international data-pooling collabo-
ration. The primary objective of the col-
laboration was to examine aspects of
screening for type 2 diabetes and im-
paired glucose tolerance across various
populations and ethnic groups. Details of
the collaboration are reported elsewhere
(8,9). For the current analysis, studies in-
cluded in the DETECT-2 database, in
which retinopathy data had been col-
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for this analysis. Additional studies with
retinopathy data identiﬁed by coinvesti-
gators through personal contact or litera-
turesearchalsowereinvitedtocontribute
datasets. Retinopathy data were available
from 12 studies in eight countries
(4,5,7,10–18). This analysis focuses on
nine studies from ﬁve countries that had
retinopathy data by grading. Participants
aged 20–79 years, including those with
known diabetes and with gradable retinal
photographs and at least one measure of
glycemia, were included. All studies were
approved by respective institutional re-
view boards and were conducted accord-
ing to the Declaration of Helsinki.
Classiﬁcation of retinopathy
The retinal photograph grading was per-
formed by individual study centers. Reti-
nopathy was classiﬁed as present or
absent for initial analysis. Where data
were available, those with retinopathy
were further classiﬁed as those having
minimal nonproliferative diabetic reti-
nopathy (NPDR), mild NPDR, moderate
NPDR, severe NPDR, or proliferative dia-
betic retinopathy (PDR) based on the in-
formation provided by individual studies
using the modiﬁed Airlie House classiﬁ-
cation levels (19), modiﬁed Early Treat-
ment Diabetic Retinopathy Study levels
(20), or the Fukuda standard (21). Lev-
els 14–20 indicate minimal NPDR, levels
30–35 or the Fukuda standard A1 indi-
cate mild NPDR, levels 40–47 or the
Fukuda standard A2 indicate moderate
NPDR, levels 50–53 or the Fukuda stan-
dard A3 indicate severe NPDR, and levels
60–90 or the Fukuda standards A4 and
B1–B4 indicate PDR. The ﬁnal retinopa-
thygradingforeachparticipantwasbased
on the diagnosis in the more severely af-
fected eye. The primary outcome used in
this study was diabetes-speciﬁc retinopa-
thy, which we deﬁned as moderate or
more severe levels of retinopathy.
Allninestudiesmeasuredplasmaglu-
cose, and six studies that measured A1C
used high-performance liquid chroma-
tography, of which ﬁve used a Diabetes
Control and Complications Trial
(DCCT)-aligned assay (5,12,14,15,18).
Statistical analysis
Prevalence of diabetes-speciﬁc retinopa-
thy was examined by 1) 0.5-unit intervals
ofglycemicmeasuresand2)vigintiles(di-
viding participants into 20 equally sized
groups) of the distribution for each mea-
sureofglycemia.Logisticregressionmod-
els were applied to test the relationships
between diabetes-speciﬁc retinopathy
and glycemia by 0.5-unit intervals and by
vigintiles of each glycemic measure, with
the lowest range as the reference. The
analyses were repeated after adjusting for
study center.
The discriminatory power of each
measure of glycemia for retinopathy was
assessed as the area under the receiver-
operating characteristic (ROC) curve
(AUC).AnAUCof1indicatesperfectdis-
criminatory power and an AUC of 0.5 in-
dicatesthatthediscriminationisnobetter
than chance. ROC curve analyses were
used to examine thresholds based on op-
timizing sensitivity and speciﬁcity. The
impact of various thresholds on the prev-
alence of diabetes was examined by ap-
plyingthesevaluesto16,381participants
withoutknowndiabeteswhohadallthree
measures of glycemia.
Sensitivity analysis was performed on
1) studies in which a DCCT-aligned assay
for A1C was used (AusDiab, Chennai Ur-
ban Rural Epidemiological Study
[CURES], Multi-Ethnic Study of Athero-
sclerosis and Air Pollution [MESA],
NHANES III, and Singapore Malay Eye
Study [SiMES]); 2) studies in which one
of the authors (T.Y.W) was personally in-
volvedinthegradingofretinopathyusing
the modiﬁed Early Treatment Diabetic
Retinopathy Study (Atherosclerosis Risk
in Communities [ARIC], AusDiab, Blue
MountainsEyeStudy[BMES],MESA,and
SiMES); 3) studies in which participants
were predominantly Caucasian (ARIC,
AusDiab, BMES, MESA, and NHANES
III); 4) studies in which participants were
Asian (CURES, Hiroshima study, and
SiMES); and 5) studies in which partici-
pants had all three measures of glycemia.
Allstatisticalanalyseswereperformedus-
ing SAS 9.1 for Windows (SAS Institute,
Cary, NC) and SPSS 16.0 for Windows
(SPSS, Chicago, IL).
RESULTS
Study participants
Intotal,44,623participantshadinforma-
tion on both the presence and severity of
retinopathy (Table 1). A total of 1,589
participants had minimal NPDR, 762 had
mildNPDR,430hadmoderateNPDR,50
had severe NPDR, and 171 had PDR. The
number of participants available for each
measure of glycemia was 41,334 for FPG,
21,334 for 2-h PG, and 27,933 for A1C.
Of these, 27,445 participants had at least
two measures and 18,533 participants
had all three measures. The characteris-
tics of participants by study are shown
in supplementary Table 1 in the on-
line appendix (available at http://care.
diabetesjournals.org/cgi/content/full/dc10-
1206/DC1).
Prevalence of retinopathy
The overall prevalence of any retinopathy
was 6.7% and 1.5% for diabetes-speciﬁc
retinopathy.Inpeoplewithknowndiabe-
tes, the prevalence of diabetes-speciﬁc
retinopathy was 9.4%, in newly diag-
nosed diabetes 1.0%, in impaired glucose
Table 1—Summary of studies included in these analyses
Name of study Country Year Age range n* Measures available
ARIC (10) U.S. 1993–1995 (visit 3) 49–73 10,873 FPG
AusDiab (5) Australia 1999–2000 25–90 2,052 FPG, 2-h PG, A1C
BMES (11) Australia 1992–1994 45–97 2,915 FPG
CURES (12) India 2002–2004 (phase III) 20–85 2,200 FPG, 2-h PG, A1C
Hiroshima study (4) Japan 1990–2004 17–99 12,873 FPG, 2-h PG, A1C
MESA (14) U.S. 2002–2004 (second examination) 45–85 5,920 FPG, A1C
NHANES III (15) U.S. 1988–1994 40–74 2,869 FPG, 2-h PG, A1C
Pima Indian study (17) U.S. 1982 (ﬁrst examination) 15–85 1,829 FPG, 2-h PG
SiMES (18) Singapore 2004 40–79 3,170 A1C
*Number of participants aged 20–79 years included in the analysis.
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glucose (1) 0.1%, and with normal glu-
cose tolerance 0.1%.
Figure 1 shows the prevalence of ret-
inopathy by 0.5-unit intervals for each
measure of glycemia for diabetes-speciﬁc
retinopathy. These plots suggest a curvi-
linear relationship for FPG and A1C and
retinopathy. Diabetes-speciﬁc retinopa-
thy was virtually absent (prevalence
0.4%) at low levels for each glycemic
measure but began to increase from the
FPG category of 6.0–6.4 mmol/l and
from the A1C category of 6.0–6.4%. The
curve for 2-h PG was ﬂatter than for FPG
and A1C, and no deﬁnite interval of in-
crease for 2-h PG was obvious.
Logistic regression adjusted for study
Figure1—Prevalenceofdiabetes-speciﬁcretinopathy(moderateormoresevereretinopathy)with95%conﬁdenceintervals,numberofretinopathy
cases, and participants within each interval by 0.5 unit intervals for FPG and 2-h PG, and A1C.
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the odds ratio (OR) for diabetes-speciﬁc
retinopathy was signiﬁcantly different
from the reference FPG level of 4.0–4.4
mmol/l was 6.5–6.9 mmol/l (OR 6.0
[95% CI 2.1–17.1]; P  0.01). The cor-
responding result for A1C was 6.5–6.9%
(16.8 [2.3–123.7]; P  0.01) compared
with an A1C of 4.0–4.4%.
Figure 2 shows the prevalence of dia-
betes-speciﬁc retinopathy by vigintiles of
the glycemic distributions. The preva-
lence of diabetes-speciﬁc retinopathy was
very low until the 15th vigintile for 2-h
PG(vigintilerange9.8–10.6mmol/l)and
until the 17th vigintile for FPG (6.4–6.8
mmol/l) and for A1C (6.1–6.2%).
Logistic regression models adjusted
for study center conﬁrmed a statistically
signiﬁcant difference in the OR for diabe-
tes-speciﬁc retinopathy compared with
the ﬁrst vigintile that occurred from the
15th vigintile for 2-h PG (vigintile range
9.8–10.6 mmol/l; OR 10.1 [95% CI 1.3–
79.4]; P  0.03), from the 17th vigintile
for FPG (6.4–6.8 mmol/l; 2.5 [1.2–5.2];
P  0.01), and from the 18th vigintile for
A1C (6.3–6.7%; 4.5 [1.4–15.2]; P 
0.01).
Supplementary Table 2 in the online
appendix shows the ROC curve analyses.
The overall discriminatory power deter-
mined by AUCs was uniformly high for
diabetes-speciﬁc retinopathy for each
measureofglycemia(0.87[95%CI0.85–
0.89] for FPG, 0.89 [0.87–0.91] for 2-h
PG, and 0.90 [0.88–0.92] for A1C). The
overlapping CIs suggests that there is no
statistical difference between the three
measures of glycemia. The performance
of a wide range of thresholds was exam-
ined, with particular attention to those
that overlapped from the continuous and
vigintile distribution plots. The thresh-
olds that optimized sensitivity and speci-
ﬁcity were 6.6 mmol/l for FPG, 13.0
mmol/lfor2-hPG,and6.4%forA1C(Ta-
ble 2). These thresholds gave similar val-
ues for positive and negative predictive
values. If these thresholds were used for
diagnosing diabetes, the prevalence of
newly diagnosed diabetes would be
11.9, 8.0, and 6.3% according to FPG,
2-h PG, and A1C, respectively. The dif-
ferences in performance based on ROC
curve statistics for the three measures of
glycemia were minor for threshold val-
ues around the above values (supple-
mentary Table 2).
Sensitivity analyses showed that the
ﬁvestudiesinwhichT.Y.Wusedthesame
retinopathy grading system or the ﬁve
studiesthatusedDCCT-alignedassaysfor
A1C measurements provided similar re-
sults to the overall study. The optimal
threshold for FPG was 6.4–6.5 mmol/l,
for A1C 6.4–6.5%, and for 2-h PG 10.1–
11.2 mmol/l.
CONCLUSIONS — The current di-
agnostic criteria for diabetes were derived
from analyses of the relationship between
retinopathyandmeasuresofglycemia(1).
Our study is the largest to examine this
association, using data from 45,000
participants from ﬁve countries, and pro-
vides the statistical power for a more de-
tailed and precise examination of
glycemic thresholds for diabetes-speciﬁc
retinopathy (moderate nonproliferative
Table 2—Threshold ranges for diabetes-speciﬁc retinopathy (moderate NPDR or more severe
retinopathy) derived from logistic regression models (adjusted for center) of the glycemic
measures by continuous distribution and vigintile distribution and ROC curve analysis
FPG (mmol/l) 2-h PG (mmol/l) A1C (%)
Logistic regression
Continuous distribution 6.5–6.9 No threshold 6.5–6.9
Vigintile distribution 6.4–6.8 9.8–10.6 6.3–6.7
ROC curve analysis 6.6 13.0 6.4
Figure 2—Prevalence of diabetes-speciﬁc retinopathy (moderate or more severe retinopathy) by vigintiles of the distribution of FPG, 2-h PG, and
A1C.
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studies (7,16) have only reported the as-
sociation of glycemic measures with any
retinopathy, which is less speciﬁc for hy-
perglycemia and is very frequently de-
tected in people without diabetes.
The association between glycemic
measures and retinopathy has tradition-
ally been investigated by plotting the
prevalence of retinopathy against the de-
cile distribution (the population divided
into 10 equal groups) of each glycemic
measure (1,2). Our large dataset allows
analysis using vigintile distributions (the
populationdividedinto20equalgroups),
whichnarrowstheglycemicrangeofeach
group. Based on logistic regression analy-
sis of these vigintile distributions, glyce-
mic thresholds for diabetes-speciﬁc
retinopathy were observed in the range of
6.4–6.8 mmol/l for FPG, 9.8–10.6
mmol/l for 2-h PG, and 6.3–6.7% for
A1C (Table 2).
The large size of this dataset enables
diabetes-speciﬁc retinopathy to be plot-
ted against measures of glycemia as a
continuous variable. A curvilinear rela-
tionship was observed, especially for FPG
and A1C, as opposed to the linear associ-
ation observed between blood pressure
and cardiovascular disease. Diabetes-
speciﬁc retinopathy was rare at low levels
of glycemia but increased from a range of
6.0–6.4 mmol/l for FPG and 6.0–6.4%
for A1C. A threshold for increasing reti-
nopathy was less obvious for 2-h PG,
probably related to the smaller number of
study participants with this measure and
diabetes-speciﬁc retinopathy. Change
point analyses, which were used previ-
ously in two population-based studies
(22), were applied to these curves in an
attempt to identify statistically signiﬁcant
thresholds, but we were unable to dem-
onstrateaclearthresholdforanyglycemic
measure by this method. This could sug-
gest that within the ranges of visually de-
tected thresholds for the three measures,
changes in the prevalence of diabetes-
speciﬁc retinopathy remain somewhat
linear.
The continuous and vigintile plots
provided a similar range of threshold val-
uesforFPGandA1C.ROCcurveanalyses
were then used to compare performance
in relation to optimizing sensitivity and
speciﬁcity of glycemic values in the range
around these thresholds. These analyses
suggest thresholds of 6.6 mmol/l for FPG
and 6.4% for A1C. The corresponding
ROC value for 2-h PG was 13.0 mmol/l.
Combining the results derived from
the vigintile distribution, continuous
plots,andROCcurveanalysessuggestcut
point values of 6.5 mmol/l for FPG and
6.5%forA1C,whichcouldbeconsidered
in deliberations on modifying the current
diagnostic criteria for diabetes. The re-
sults for 2-h PG were too inconsistent to
consider modifying the current diagnos-
tic cut point of 11.1 mmol/l.
It should be noted that these values
do not result in equivalent estimates for
prevalent diabetes. This has been an on-
going issue with the current diagnostic
criteria, whereby using FPG alone or an
oral glucose tolerance test to diagnose di-
abetes gives different diabetes prevalence
(23). From our data (supplementary Ta-
ble 2), lowering the FPG to 6.5 mmol/l
would result in a diabetes prevalence of
13.0% based on FPG alone and 18.6%
based on an oral glucose tolerance test
usinganFPGof6.5mmol/lora2-hPGof
11.1 mmol/l. The prevalence of diabetes
deﬁned by an A1C of 6.5% is consider-
ably lower (5.7%). This discrepancy in
prevalence may be problematic for epide-
miological studies but is not necessarily a
disadvantage for individual patient care.
An A1C of 6.5% was associated with a
higher sensitivity and speciﬁcity than an
FPGof6.5mmol/landahigherspeciﬁcity
than a 2-h PG of 11.1 mmol/l. In other
words, fewer people would be identiﬁed
as having diabetes, but this would not
compromise the identiﬁcation of people
with diabetes-speciﬁc retinopathy.
Whether this would have any deleterious
ramiﬁcations in relation to identifying in-
dividuals at increased risk of other micro-
vascular or macrovascular disease
remains to be determined.
This study necessarily included pop-
ulationsfromdifferentcountrieswithvar-
ious racial/ethnic backgrounds. There
have been reports of differences in A1C
levels independent of glucose between
black, white, and South Asian popula-
tions (24,25). In our study, subgroup
analysis by Asian and predominantly
Caucasian populations showed no differ-
ence in the optimal A1C threshold (6.4%
for both). However, our study was not
designed to have and did not have sufﬁ-
cient numbers to examine a potential
black/white difference.
Strengths of this study include its
large sample size, which was drawn from
populations across different countries
and racial/ethnic groups; the ability to fo-
cus on diabetes-speciﬁc retinopathy; and
availability of data to examine three gly-
cemic measures. Our study has some lim-
itations. First, this study was based on
cross-sectional data, whereas diagnostic
thresholds would ideally be informed by
incidence data of diabetes complications.
Second, the methods used to assess and
classify retinopathy differed between
studies, and it was not possible to inde-
pendently review the grading of all
photographs. Nevertheless, inter- and in-
traobserverconsistencyforretinopathyin
the different studies was of the order of
80–98% (3,10,15) and misclassiﬁcation,
especially for moderate or more severe
forms of retinopathy, is likely to be mini-
mal but cannot be entirely eliminated.
Furthermore, analysis of the studies in
which T.Y.W. was involved in the stan-
dardized grading of retinal photographs
showed cut points for FPG and A1C sim-
ilar to our entire study cohort. Third, no
qualityassuranceofmeasuresofglycemia
could be applied across the studies. Nev-
ertheless, all studies measured A1C using
high-performance liquid chromatogra-
phy, and analysis of the ﬁve studies that
used a DCCT-aligned assay showed an
A1C cut point of 6.4–6.5%. Fourth, the
Hiroshima study, with its large sample
size, and the Pima Indian study, with its
high prevalence of diabetes-speciﬁc reti-
nopathy,mayhaveinﬂuencedtheresults.
However, sensitivity analyses that ex-
cluded these two studies did not alter the
overall results. Finally, not all included
studies were randomly sampled popula-
tions (e.g., MESA) and some (e.g., Aus-
Diab) oversampled people with diabetes
and/or prediabetes. Common to all such
analyses is the issue of whether to include
people with previously diagnosed diabe-
tes. If people with known diabetes cur-
rently receiving blood glucose–lowering
treatment are included, the population-
based characteristics of the study sample
are maintained, but a bias associated with
treatment-induced effects on glycemia is
introduced and the level of glycemia as-
sessed in each study may be lower than
that which led to retinopathy. Excluding
people with treated diabetes from the
analyses eliminates this bias but changes
the characteristics of the population by
eliminating many individuals with reti-
nopathy,makingitmuchmoredifﬁcultto
identifyathreshold(2,7).Largeincidence
studies are needed to resolve these issues
anddeterminetheoptimallevelsofglyce-
mia that predict the development of dia-
betes-speciﬁc retinopathy.
In summary, this pooled analysis of
glycemia and diabetes-speciﬁc retinopa-
thy among close to 45,000 participants
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on glucose-speciﬁc and A1C diabetes di-
agnostic thresholds. Our results demon-
strate narrow glycemic threshold ranges
for the presence of diabetes-speciﬁc reti-
nopathy and suggest that the current dia-
betes diagnostic level for FPG should be
lowered to 6.5 mmol/l and that an A1C of
6.5% is a suitable alternative diagnostic
criterion.
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